- Home
- GYRE vs EH Comparison
GYRE vs EH Comparison
Compare GYRE & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- EH
- Stock Information
- Founded
- GYRE 2002
- EH 2014
- Country
- GYRE United States
- EH China
- Employees
- GYRE N/A
- EH N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- EH Military/Government/Technical
- Sector
- GYRE Health Care
- EH Industrials
- Exchange
- GYRE Nasdaq
- EH Nasdaq
- Market Cap
- GYRE 1.3B
- EH 1.1B
- IPO Year
- GYRE N/A
- EH 2019
- Fundamental
- Price
- GYRE $11.42
- EH $14.37
- Analyst Decision
- GYRE
- EH Buy
- Analyst Count
- GYRE 0
- EH 1
- Target Price
- GYRE N/A
- EH $27.50
- AVG Volume (30 Days)
- GYRE 126.3K
- EH 1.7M
- Earning Date
- GYRE 11-13-2024
- EH 11-18-2024
- Dividend Yield
- GYRE N/A
- EH N/A
- EPS Growth
- GYRE N/A
- EH N/A
- EPS
- GYRE N/A
- EH N/A
- Revenue
- GYRE $105,033,000.00
- EH $49,679,663.00
- Revenue This Year
- GYRE $25.32
- EH N/A
- Revenue Next Year
- GYRE $12.95
- EH $97.81
- P/E Ratio
- GYRE N/A
- EH N/A
- Revenue Growth
- GYRE N/A
- EH 355.50
- 52 Week Low
- GYRE $8.26
- EH $9.51
- 52 Week High
- GYRE $30.40
- EH $22.98
- Technical
- Relative Strength Index (RSI)
- GYRE 54.43
- EH 44.57
- Support Level
- GYRE $9.61
- EH $14.16
- Resistance Level
- GYRE $12.58
- EH $16.93
- Average True Range (ATR)
- GYRE 1.12
- EH 0.68
- MACD
- GYRE 0.16
- EH -0.04
- Stochastic Oscillator
- GYRE 79.51
- EH 16.61
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About EH EHang Holdings Limited ADS
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.